nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.49	1	CbGbCtD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL3L1—acquired immunodeficiency syndrome	0.0127	0.105	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL4—acquired immunodeficiency syndrome	0.00696	0.0574	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00616	0.0508	CbGpPWpGaD
Raltegravir—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.0059	0.0965	CbGeAlD
Raltegravir—CCR1—lymphoid tissue—acquired immunodeficiency syndrome	0.00559	0.0914	CbGeAlD
Raltegravir—CCR1—digestive system—acquired immunodeficiency syndrome	0.00552	0.0903	CbGeAlD
Raltegravir—CCR1—blood—acquired immunodeficiency syndrome	0.00526	0.086	CbGeAlD
Raltegravir—CCR1—bone marrow—acquired immunodeficiency syndrome	0.00509	0.0832	CbGeAlD
Raltegravir—CCR1—spinal cord—acquired immunodeficiency syndrome	0.00507	0.0829	CbGeAlD
Raltegravir—CCR1—vagina—acquired immunodeficiency syndrome	0.00487	0.0797	CbGeAlD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00478	0.0394	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL3—acquired immunodeficiency syndrome	0.00475	0.0392	CbGpPWpGaD
Raltegravir—CCR1—lung—acquired immunodeficiency syndrome	0.00461	0.0754	CbGeAlD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR2—acquired immunodeficiency syndrome	0.0043	0.0355	CbGpPWpGaD
Raltegravir—CCR1—nervous system—acquired immunodeficiency syndrome	0.00427	0.0698	CbGeAlD
Raltegravir—CCR1—central nervous system—acquired immunodeficiency syndrome	0.00411	0.0672	CbGeAlD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL12—acquired immunodeficiency syndrome	0.00404	0.0334	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCR4—acquired immunodeficiency syndrome	0.00404	0.0334	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00344	0.0284	CbGpPWpGaD
Raltegravir—CCR1—brain—acquired immunodeficiency syndrome	0.00326	0.0534	CbGeAlD
Raltegravir—CCR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00323	0.0267	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00321	0.0265	CbGpPWpGaD
Raltegravir—CCR1—lymph node—acquired immunodeficiency syndrome	0.00315	0.0516	CbGeAlD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL5—acquired immunodeficiency syndrome	0.00307	0.0254	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0029	0.0239	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR5—acquired immunodeficiency syndrome	0.00277	0.0229	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00262	0.0216	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00244	0.0201	CbGpPWpGaD
Raltegravir—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.00227	0.0371	CbGeAlD
Raltegravir—CCR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00222	0.0183	CbGpPWpGaD
Raltegravir—UGT1A1—blood—acquired immunodeficiency syndrome	0.00216	0.0354	CbGeAlD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00194	0.016	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00179	0.0148	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00176	0.0145	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00162	0.0134	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00152	0.0126	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00152	0.0126	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00148	0.0122	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00136	0.0113	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00134	0.011	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00128	0.0106	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00128	0.0106	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00127	0.0105	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00125	0.0103	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.0012	0.0099	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00119	0.00983	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00116	0.00955	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00109	0.00896	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00104	0.0086	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00102	0.00842	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00102	0.00842	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000976	0.00806	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000914	0.00754	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000879	0.00726	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000826	0.00682	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000816	0.00674	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000777	0.00641	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000777	0.00641	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000776	0.00641	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000759	0.00626	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00074	0.00611	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000699	0.00577	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000686	0.00566	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000591	0.00488	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000532	0.00439	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000469	0.00387	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000467	0.00385	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000448	0.0037	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000448	0.0037	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000439	0.00363	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000439	0.00362	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000439	0.00362	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000424	0.0035	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000405	0.00335	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000399	0.00329	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000399	0.00329	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000391	0.00322	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000334	0.00276	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000329	0.00272	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000303	0.0025	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000301	0.00248	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000299	0.00247	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000284	0.00235	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000277	0.00229	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000273	0.00226	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00025	0.00207	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000236	0.00194	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000236	0.00194	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000179	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000176	0.00146	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000174	0.00143	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TAT—acquired immunodeficiency syndrome	0.000164	0.00136	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000161	0.00133	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000158	0.0013	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00014	0.00115	CbGpPWpGaD
Raltegravir—Dermatitis—Didanosine—acquired immunodeficiency syndrome	9.35e-05	0.000286	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.33e-05	0.00077	CbGpPWpGaD
Raltegravir—Cough—Ritonavir—acquired immunodeficiency syndrome	9.31e-05	0.000284	CcSEcCtD
Raltegravir—Headache—Didanosine—acquired immunodeficiency syndrome	9.3e-05	0.000284	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.28e-05	0.000766	CbGpPWpGaD
Raltegravir—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	9.27e-05	0.000283	CcSEcCtD
Raltegravir—Malaise—Saquinavir—acquired immunodeficiency syndrome	9.26e-05	0.000283	CcSEcCtD
Raltegravir—Somnolence—Indinavir—acquired immunodeficiency syndrome	9.26e-05	0.000283	CcSEcCtD
Raltegravir—Asthenia—Stavudine—acquired immunodeficiency syndrome	9.24e-05	0.000282	CcSEcCtD
Raltegravir—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	9.23e-05	0.000282	CcSEcCtD
Raltegravir—Vertigo—Saquinavir—acquired immunodeficiency syndrome	9.22e-05	0.000282	CcSEcCtD
Raltegravir—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	9.22e-05	0.000282	CcSEcCtD
Raltegravir—Hypertension—Ritonavir—acquired immunodeficiency syndrome	9.21e-05	0.000281	CcSEcCtD
Raltegravir—Tremor—Lamivudine—acquired immunodeficiency syndrome	9.18e-05	0.00028	CcSEcCtD
Raltegravir—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	9.17e-05	0.00028	CcSEcCtD
Raltegravir—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	9.16e-05	0.00028	CcSEcCtD
Raltegravir—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	9.14e-05	0.000279	CcSEcCtD
Raltegravir—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	9.14e-05	0.000279	CcSEcCtD
Raltegravir—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	9.13e-05	0.000279	CcSEcCtD
Raltegravir—Pruritus—Stavudine—acquired immunodeficiency syndrome	9.11e-05	0.000278	CcSEcCtD
Raltegravir—Asthenia—Abacavir—acquired immunodeficiency syndrome	9.11e-05	0.000278	CcSEcCtD
Raltegravir—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	9.1e-05	0.000278	CcSEcCtD
Raltegravir—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	9.09e-05	0.000278	CcSEcCtD
Raltegravir—Chest pain—Ritonavir—acquired immunodeficiency syndrome	9.08e-05	0.000277	CcSEcCtD
Raltegravir—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	9.08e-05	0.000277	CcSEcCtD
Raltegravir—Myalgia—Ritonavir—acquired immunodeficiency syndrome	9.08e-05	0.000277	CcSEcCtD
Raltegravir—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	9.05e-05	0.000276	CcSEcCtD
Raltegravir—Anaemia—Lamivudine—acquired immunodeficiency syndrome	9.05e-05	0.000276	CcSEcCtD
Raltegravir—Anxiety—Ritonavir—acquired immunodeficiency syndrome	9.05e-05	0.000276	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	9.02e-05	0.000275	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.99e-05	0.000275	CcSEcCtD
Raltegravir—Pruritus—Abacavir—acquired immunodeficiency syndrome	8.98e-05	0.000274	CcSEcCtD
Raltegravir—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.98e-05	0.000274	CcSEcCtD
Raltegravir—Discomfort—Ritonavir—acquired immunodeficiency syndrome	8.97e-05	0.000274	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.96e-05	0.000274	CcSEcCtD
Raltegravir—Cough—Saquinavir—acquired immunodeficiency syndrome	8.96e-05	0.000274	CcSEcCtD
Raltegravir—Pain—Indinavir—acquired immunodeficiency syndrome	8.9e-05	0.000272	CcSEcCtD
Raltegravir—Constipation—Indinavir—acquired immunodeficiency syndrome	8.9e-05	0.000272	CcSEcCtD
Raltegravir—Insomnia—Efavirenz—acquired immunodeficiency syndrome	8.9e-05	0.000272	CcSEcCtD
Raltegravir—Urticaria—Zidovudine—acquired immunodeficiency syndrome	8.89e-05	0.000272	CcSEcCtD
Raltegravir—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	8.88e-05	0.000271	CcSEcCtD
Raltegravir—Hypertension—Saquinavir—acquired immunodeficiency syndrome	8.86e-05	0.000271	CcSEcCtD
Raltegravir—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	8.85e-05	0.00027	CcSEcCtD
Raltegravir—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.85e-05	0.00027	CcSEcCtD
Raltegravir—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.84e-05	0.00027	CcSEcCtD
Raltegravir—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	8.83e-05	0.00027	CcSEcCtD
Raltegravir—Malaise—Lamivudine—acquired immunodeficiency syndrome	8.83e-05	0.00027	CcSEcCtD
Raltegravir—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.81e-05	0.000269	CcSEcCtD
Raltegravir—Nausea—Didanosine—acquired immunodeficiency syndrome	8.81e-05	0.000269	CcSEcCtD
Raltegravir—Vertigo—Lamivudine—acquired immunodeficiency syndrome	8.8e-05	0.000269	CcSEcCtD
Raltegravir—Confusional state—Ritonavir—acquired immunodeficiency syndrome	8.78e-05	0.000268	CcSEcCtD
Raltegravir—Somnolence—Efavirenz—acquired immunodeficiency syndrome	8.75e-05	0.000267	CcSEcCtD
Raltegravir—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.74e-05	0.000267	CcSEcCtD
Raltegravir—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.74e-05	0.000267	CcSEcCtD
Raltegravir—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.74e-05	0.000267	CcSEcCtD
Raltegravir—Anxiety—Saquinavir—acquired immunodeficiency syndrome	8.71e-05	0.000266	CcSEcCtD
Raltegravir—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.68e-05	0.000265	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.68e-05	0.000265	CcSEcCtD
Raltegravir—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	8.66e-05	0.000265	CcSEcCtD
Raltegravir—Discomfort—Saquinavir—acquired immunodeficiency syndrome	8.64e-05	0.000264	CcSEcCtD
Raltegravir—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	8.58e-05	0.000262	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.58e-05	0.000262	CcSEcCtD
Raltegravir—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.55e-05	0.000261	CcSEcCtD
Raltegravir—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.55e-05	0.000261	CcSEcCtD
Raltegravir—Cough—Lamivudine—acquired immunodeficiency syndrome	8.55e-05	0.000261	CcSEcCtD
Raltegravir—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.54e-05	0.000261	CcSEcCtD
Raltegravir—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.54e-05	0.000261	CcSEcCtD
Raltegravir—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.52e-05	0.00026	CcSEcCtD
Raltegravir—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.52e-05	0.00026	CcSEcCtD
Raltegravir—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.51e-05	0.00026	CcSEcCtD
Raltegravir—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.51e-05	0.00026	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.49e-05	0.000259	CcSEcCtD
Raltegravir—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.48e-05	0.000259	CcSEcCtD
Raltegravir—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.48e-05	0.000259	CcSEcCtD
Raltegravir—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.46e-05	0.000258	CcSEcCtD
Raltegravir—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.45e-05	0.000258	CcSEcCtD
Raltegravir—Confusional state—Saquinavir—acquired immunodeficiency syndrome	8.45e-05	0.000258	CcSEcCtD
Raltegravir—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	8.42e-05	0.000257	CcSEcCtD
Raltegravir—Pain—Efavirenz—acquired immunodeficiency syndrome	8.41e-05	0.000257	CcSEcCtD
Raltegravir—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.41e-05	0.000257	CcSEcCtD
Raltegravir—Rash—Nevirapine—acquired immunodeficiency syndrome	8.41e-05	0.000257	CcSEcCtD
Raltegravir—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.4e-05	0.000257	CcSEcCtD
Raltegravir—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.39e-05	0.000256	CcSEcCtD
Raltegravir—Somnolence—Delavirdine—acquired immunodeficiency syndrome	8.37e-05	0.000256	CcSEcCtD
Raltegravir—Headache—Nevirapine—acquired immunodeficiency syndrome	8.36e-05	0.000255	CcSEcCtD
Raltegravir—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.34e-05	0.000255	CcSEcCtD
Raltegravir—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.34e-05	0.000255	CcSEcCtD
Raltegravir—Myalgia—Lamivudine—acquired immunodeficiency syndrome	8.34e-05	0.000255	CcSEcCtD
Raltegravir—Infection—Saquinavir—acquired immunodeficiency syndrome	8.32e-05	0.000254	CcSEcCtD
Raltegravir—Anxiety—Lamivudine—acquired immunodeficiency syndrome	8.31e-05	0.000254	CcSEcCtD
Raltegravir—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	8.29e-05	0.000253	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.28e-05	0.000253	CcSEcCtD
Raltegravir—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.27e-05	0.000253	CcSEcCtD
Raltegravir—Discomfort—Lamivudine—acquired immunodeficiency syndrome	8.24e-05	0.000252	CcSEcCtD
Raltegravir—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.23e-05	0.000251	CcSEcCtD
Raltegravir—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.23e-05	0.000251	CcSEcCtD
Raltegravir—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.22e-05	0.000251	CcSEcCtD
Raltegravir—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.22e-05	0.000251	CcSEcCtD
Raltegravir—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.2e-05	0.000251	CcSEcCtD
Raltegravir—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.19e-05	0.00025	CcSEcCtD
Raltegravir—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.18e-05	0.00025	CcSEcCtD
Raltegravir—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.15e-05	0.000249	CcSEcCtD
Raltegravir—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.15e-05	0.000249	CcSEcCtD
Raltegravir—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.14e-05	0.000249	CcSEcCtD
Raltegravir—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	8.14e-05	0.000249	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	8.13e-05	0.000248	CcSEcCtD
Raltegravir—Rash—Stavudine—acquired immunodeficiency syndrome	8.12e-05	0.000248	CcSEcCtD
Raltegravir—Fatigue—Delavirdine—acquired immunodeficiency syndrome	8.12e-05	0.000248	CcSEcCtD
Raltegravir—Dermatitis—Stavudine—acquired immunodeficiency syndrome	8.11e-05	0.000248	CcSEcCtD
Raltegravir—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	8.11e-05	0.000248	CcSEcCtD
Raltegravir—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	8.1e-05	0.000247	CcSEcCtD
Raltegravir—Headache—Nelfinavir—acquired immunodeficiency syndrome	8.09e-05	0.000247	CcSEcCtD
Raltegravir—Headache—Stavudine—acquired immunodeficiency syndrome	8.07e-05	0.000247	CcSEcCtD
Raltegravir—Vomiting—Abacavir—acquired immunodeficiency syndrome	8.07e-05	0.000246	CcSEcCtD
Raltegravir—Confusional state—Lamivudine—acquired immunodeficiency syndrome	8.06e-05	0.000246	CcSEcCtD
Raltegravir—Pain—Delavirdine—acquired immunodeficiency syndrome	8.05e-05	0.000246	CcSEcCtD
Raltegravir—Constipation—Delavirdine—acquired immunodeficiency syndrome	8.05e-05	0.000246	CcSEcCtD
Raltegravir—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	8.04e-05	0.000246	CcSEcCtD
Raltegravir—Asthenia—Zidovudine—acquired immunodeficiency syndrome	8.03e-05	0.000245	CcSEcCtD
Raltegravir—Rash—Abacavir—acquired immunodeficiency syndrome	8e-05	0.000244	CcSEcCtD
Raltegravir—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.99e-05	0.000244	CcSEcCtD
Raltegravir—Headache—Abacavir—acquired immunodeficiency syndrome	7.95e-05	0.000243	CcSEcCtD
Raltegravir—Infection—Lamivudine—acquired immunodeficiency syndrome	7.94e-05	0.000243	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.93e-05	0.000242	CcSEcCtD
Raltegravir—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.92e-05	0.000242	CcSEcCtD
Raltegravir—Pruritus—Zidovudine—acquired immunodeficiency syndrome	7.92e-05	0.000242	CcSEcCtD
Raltegravir—Insomnia—Ritonavir—acquired immunodeficiency syndrome	7.87e-05	0.00024	CcSEcCtD
Raltegravir—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000239	CcSEcCtD
Raltegravir—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.83e-05	0.000239	CcSEcCtD
Raltegravir—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	7.82e-05	0.000239	CcSEcCtD
Raltegravir—Urticaria—Efavirenz—acquired immunodeficiency syndrome	7.82e-05	0.000239	CcSEcCtD
Raltegravir—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.78e-05	0.000238	CcSEcCtD
Raltegravir—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.78e-05	0.000238	CcSEcCtD
Raltegravir—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.76e-05	0.000237	CcSEcCtD
Raltegravir—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	7.76e-05	0.000237	CcSEcCtD
Raltegravir—Somnolence—Ritonavir—acquired immunodeficiency syndrome	7.74e-05	0.000236	CcSEcCtD
Raltegravir—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	7.73e-05	0.000236	CcSEcCtD
Raltegravir—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.7e-05	0.000235	CcSEcCtD
Raltegravir—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.68e-05	0.000234	CcSEcCtD
Raltegravir—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.67e-05	0.000234	CcSEcCtD
Raltegravir—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	7.66e-05	0.000234	CcSEcCtD
Raltegravir—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.66e-05	0.000234	CcSEcCtD
Raltegravir—Nausea—Stavudine—acquired immunodeficiency syndrome	7.65e-05	0.000234	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.63e-05	0.000233	CcSEcCtD
Raltegravir—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.58e-05	0.000231	CcSEcCtD
Raltegravir—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.57e-05	0.000231	CcSEcCtD
Raltegravir—Nausea—Abacavir—acquired immunodeficiency syndrome	7.54e-05	0.00023	CcSEcCtD
Raltegravir—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.52e-05	0.00023	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.52e-05	0.00023	CcSEcCtD
Raltegravir—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.5e-05	0.000229	CcSEcCtD
Raltegravir—Urticaria—Delavirdine—acquired immunodeficiency syndrome	7.48e-05	0.000228	CcSEcCtD
Raltegravir—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.47e-05	0.000228	CcSEcCtD
Raltegravir—Somnolence—Saquinavir—acquired immunodeficiency syndrome	7.45e-05	0.000228	CcSEcCtD
Raltegravir—Pain—Ritonavir—acquired immunodeficiency syndrome	7.44e-05	0.000227	CcSEcCtD
Raltegravir—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.44e-05	0.000227	CcSEcCtD
Raltegravir—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.44e-05	0.000227	CcSEcCtD
Raltegravir—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.44e-05	0.000227	CcSEcCtD
Raltegravir—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.4e-05	0.000226	CcSEcCtD
Raltegravir—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.38e-05	0.000225	CcSEcCtD
Raltegravir—Pruritus—Indinavir—acquired immunodeficiency syndrome	7.37e-05	0.000225	CcSEcCtD
Raltegravir—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.28e-05	0.000222	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.28e-05	0.000222	CcSEcCtD
Raltegravir—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.25e-05	0.000221	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.23e-05	0.000221	CcSEcCtD
Raltegravir—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.23e-05	0.000221	CcSEcCtD
Raltegravir—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.22e-05	0.000221	CcSEcCtD
Raltegravir—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.18e-05	0.000219	CcSEcCtD
Raltegravir—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.17e-05	0.000219	CcSEcCtD
Raltegravir—Pain—Saquinavir—acquired immunodeficiency syndrome	7.16e-05	0.000219	CcSEcCtD
Raltegravir—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.16e-05	0.000219	CcSEcCtD
Raltegravir—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.12e-05	0.000218	CcSEcCtD
Raltegravir—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.12e-05	0.000217	CcSEcCtD
Raltegravir—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	7.12e-05	0.000217	CcSEcCtD
Raltegravir—Somnolence—Lamivudine—acquired immunodeficiency syndrome	7.11e-05	0.000217	CcSEcCtD
Raltegravir—Rash—Zidovudine—acquired immunodeficiency syndrome	7.06e-05	0.000216	CcSEcCtD
Raltegravir—Asthenia—Efavirenz—acquired immunodeficiency syndrome	7.06e-05	0.000216	CcSEcCtD
Raltegravir—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	7.05e-05	0.000215	CcSEcCtD
Raltegravir—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	7.04e-05	0.000215	CcSEcCtD
Raltegravir—Headache—Zidovudine—acquired immunodeficiency syndrome	7.01e-05	0.000214	CcSEcCtD
Raltegravir—Pruritus—Efavirenz—acquired immunodeficiency syndrome	6.96e-05	0.000213	CcSEcCtD
Raltegravir—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000212	CcSEcCtD
Raltegravir—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	6.94e-05	0.000212	CcSEcCtD
Raltegravir—Urticaria—Ritonavir—acquired immunodeficiency syndrome	6.92e-05	0.000211	CcSEcCtD
Raltegravir—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	6.9e-05	0.000211	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.9e-05	0.000211	CcSEcCtD
Raltegravir—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.89e-05	0.00021	CcSEcCtD
Raltegravir—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.89e-05	0.00021	CcSEcCtD
Raltegravir—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	6.88e-05	0.00021	CcSEcCtD
Raltegravir—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.88e-05	0.00021	CcSEcCtD
Raltegravir—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	6.85e-05	0.000209	CcSEcCtD
Raltegravir—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.83e-05	0.000209	CcSEcCtD
Raltegravir—Pain—Lamivudine—acquired immunodeficiency syndrome	6.83e-05	0.000209	CcSEcCtD
Raltegravir—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.75e-05	0.000206	CcSEcCtD
Raltegravir—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.73e-05	0.000206	CcSEcCtD
Raltegravir—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.66e-05	0.000203	CcSEcCtD
Raltegravir—Urticaria—Saquinavir—acquired immunodeficiency syndrome	6.66e-05	0.000203	CcSEcCtD
Raltegravir—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.65e-05	0.000203	CcSEcCtD
Raltegravir—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.62e-05	0.000202	CcSEcCtD
Raltegravir—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.62e-05	0.000202	CcSEcCtD
Raltegravir—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.62e-05	0.000202	CcSEcCtD
Raltegravir—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.59e-05	0.000201	CcSEcCtD
Raltegravir—Rash—Indinavir—acquired immunodeficiency syndrome	6.57e-05	0.000201	CcSEcCtD
Raltegravir—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.56e-05	0.0002	CcSEcCtD
Raltegravir—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.54e-05	0.0002	CcSEcCtD
Raltegravir—Headache—Indinavir—acquired immunodeficiency syndrome	6.52e-05	0.000199	CcSEcCtD
Raltegravir—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.51e-05	0.000199	CcSEcCtD
Raltegravir—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.44e-05	0.000197	CcSEcCtD
Raltegravir—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.41e-05	0.000196	CcSEcCtD
Raltegravir—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.35e-05	0.000194	CcSEcCtD
Raltegravir—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.32e-05	0.000193	CcSEcCtD
Raltegravir—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.32e-05	0.000193	CcSEcCtD
Raltegravir—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.26e-05	0.000191	CcSEcCtD
Raltegravir—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.25e-05	0.000191	CcSEcCtD
Raltegravir—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.22e-05	0.00019	CcSEcCtD
Raltegravir—Rash—Efavirenz—acquired immunodeficiency syndrome	6.2e-05	0.000189	CcSEcCtD
Raltegravir—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.2e-05	0.000189	CcSEcCtD
Raltegravir—Nausea—Indinavir—acquired immunodeficiency syndrome	6.19e-05	0.000189	CcSEcCtD
Raltegravir—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.17e-05	0.000189	CcSEcCtD
Raltegravir—Headache—Efavirenz—acquired immunodeficiency syndrome	6.16e-05	0.000188	CcSEcCtD
Raltegravir—Pruritus—Ritonavir—acquired immunodeficiency syndrome	6.16e-05	0.000188	CcSEcCtD
Raltegravir—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.01e-05	0.000184	CcSEcCtD
Raltegravir—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.99e-05	0.000183	CcSEcCtD
Raltegravir—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.96e-05	0.000182	CcSEcCtD
Raltegravir—Rash—Delavirdine—acquired immunodeficiency syndrome	5.94e-05	0.000181	CcSEcCtD
Raltegravir—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.93e-05	0.000181	CcSEcCtD
Raltegravir—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.93e-05	0.000181	CcSEcCtD
Raltegravir—Headache—Delavirdine—acquired immunodeficiency syndrome	5.9e-05	0.00018	CcSEcCtD
Raltegravir—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	5.89e-05	0.00018	CcSEcCtD
Raltegravir—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.84e-05	0.000178	CcSEcCtD
Raltegravir—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.76e-05	0.000176	CcSEcCtD
Raltegravir—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.73e-05	0.000175	CcSEcCtD
Raltegravir—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.73e-05	0.000175	CcSEcCtD
Raltegravir—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.65e-05	0.000173	CcSEcCtD
Raltegravir—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.59e-05	0.000171	CcSEcCtD
Raltegravir—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.54e-05	0.000169	CcSEcCtD
Raltegravir—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.53e-05	0.000169	CcSEcCtD
Raltegravir—Rash—Ritonavir—acquired immunodeficiency syndrome	5.49e-05	0.000168	CcSEcCtD
Raltegravir—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.48e-05	0.000167	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.48e-05	0.000452	CbGpPWpGaD
Raltegravir—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.47e-05	0.000167	CcSEcCtD
Raltegravir—Headache—Ritonavir—acquired immunodeficiency syndrome	5.45e-05	0.000167	CcSEcCtD
Raltegravir—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.33e-05	0.000163	CcSEcCtD
Raltegravir—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.29e-05	0.000161	CcSEcCtD
Raltegravir—Rash—Saquinavir—acquired immunodeficiency syndrome	5.28e-05	0.000161	CcSEcCtD
Raltegravir—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.28e-05	0.000161	CcSEcCtD
Raltegravir—Headache—Saquinavir—acquired immunodeficiency syndrome	5.25e-05	0.00016	CcSEcCtD
Raltegravir—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.17e-05	0.000158	CcSEcCtD
Raltegravir—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.08e-05	0.000155	CcSEcCtD
Raltegravir—Rash—Lamivudine—acquired immunodeficiency syndrome	5.04e-05	0.000154	CcSEcCtD
Raltegravir—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000154	CcSEcCtD
Raltegravir—Headache—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000153	CcSEcCtD
Raltegravir—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.98e-05	0.000152	CcSEcCtD
Raltegravir—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.75e-05	0.000145	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	2.87e-05	0.000237	CbGpPWpGaD
